CRUCELL AND UCB SIGN STAR LICENSE AGREEMENT

Dutch biotechnology company Crucell N.V. announced that it has signed a STAR licensing agreement with UCB, a leading biopharmaceutical company with headquarters in Brussels, making UCB the first European STAR licensee. The agreement covers a 5-year non-exclusive STAR research license for the production of monoclonal antibodies. Yahoo Finance (http://biz.yahoo.com/iw/060907/0160775.html)